MCK:NYSEMcKesson Corporation Analysis
Data as of 2026-06-05 - not real-time
$756.95
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
McKesson’s stock is trading at $756.95, comfortably above its 20‑day SMA of $749.96 but still below the 50‑day ($807.91) and 200‑day ($819.66) averages, indicating a short‑term bounce within a longer‑term bearish backdrop. The RSI sits at 44.3, suggesting neutral momentum, while the MACD histogram is positive (+3.21) and the MACD signal is flagged “bullish,” hinting at a possible near‑term upside. The price is perched near the calculated support of $723.68 and well under the resistance level of $782.48, giving a clear technical range for the coming weeks. Volatility over the past 30 days is elevated at ~29.5%, and the max drawdown of 27% underscores the stock’s price swings, though beta is essentially flat (‑0.06), implying limited market‑wide correlation. Stable volume trends support the view that the recent price movement is not driven by an abnormal surge in trading activity. Overall, the technical picture points to a modest upside to the $782 resistance, with downside risk limited by the nearby support.
On the fundamentals side, revenue grew 6% YoY to $403.4 B and Q1 earnings beat consensus by 1.1%, delivering non‑GAAP EPS of $11.69. The company trades at a forward P/E of 15.0 versus an industry average of 27.7, and its price‑to‑sales ratio of 0.23 is exceptionally low, signaling a value‑oriented pricing. A discounted cash‑flow model places fair value at $760.7, implying roughly a 25% upside from the current price. The dividend yield is modest at 0.43% with a payout ratio of just 8.3%, indicating strong sustainability. Despite a negative book value per share (‑$18.1) and a negative P/B, the firm generates robust free cash flow ($5.66 B) and carries a manageable net‑debt position. Analyst consensus is a “strong buy” with a median target of $945, reinforcing the upside thesis.
On the fundamentals side, revenue grew 6% YoY to $403.4 B and Q1 earnings beat consensus by 1.1%, delivering non‑GAAP EPS of $11.69. The company trades at a forward P/E of 15.0 versus an industry average of 27.7, and its price‑to‑sales ratio of 0.23 is exceptionally low, signaling a value‑oriented pricing. A discounted cash‑flow model places fair value at $760.7, implying roughly a 25% upside from the current price. The dividend yield is modest at 0.43% with a payout ratio of just 8.3%, indicating strong sustainability. Despite a negative book value per share (‑$18.1) and a negative P/B, the firm generates robust free cash flow ($5.66 B) and carries a manageable net‑debt position. Analyst consensus is a “strong buy” with a median target of $945, reinforcing the upside thesis.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 8/10
Key Factors
- price above 20‑day SMA
- bullish MACD histogram
- valuation upside to fair value
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- 6% revenue growth
- forward P/E well below industry average
- strong analyst consensus
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- sustainable dividend with low payout ratio
- robust free cash flow generation
- defensive position in healthcare distribution sector
Key Metrics & Analysis
Financial Health
Revenue Growth6.00%
Profit Margin1.18%
P/E Ratio19.7
ROA4.99%
P/B Ratio-41.8
Op. Cash Flow$6.2B
Free Cash Flow$5.7B
Industry P/E27.7
Technical Analysis
TrendBearish
RSI44.3
Support$723.68
Resistance$782.48
MA 20$749.96
MA 50$807.91
MA 200$819.66
MACDBullish
VolumeStable
Fear & Greed Index93.93
Valuation
Fair Value$760.71
Target Price$949.73
Upside/Downside25.47%
GradeUndervalued
TypeValue
Dividend Yield0.43%
Risk Assessment
Beta-0.06
Volatility29.49%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.